Site-Selective Antibody Conjugation with Dibromopyrazines

In recent years, antibody conjugates have evolved as state-of-the-art options for diagnostic and therapeutic applications. During site-selective antibody conjugation, incomplete rebridging of antibody chains limits the homogeneity of conjugates and calls for the development of new rebridging agents. Herein, we report a dibromopyrazine derivative optimized to reach highly homogeneous conjugates rapidly and with high conversion on rebridging of trastuzumab, even providing a feasible route for antibody modification in acidic conditions. Furthermore, coupling a fluorescent dye and a cytotoxic drug resulted in effective antibody conjugates with excellent serum stability and <i>in vitro</i> selectivity, demonstrating the utility of the dibromopyrazine rebridging agent to produce on-demand future antibody conjugates for diagnostic or therapeutic applications.

Authors

Institutions

Publication Details

Journal
Bioconjugate Chemistry
Published
2024-08-16
DOI
https://doi.org/10.1021/acs.bioconjchem.4c00296
Citations
5
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
2.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Site-Selective Antibody Conjugation with Dibromopyrazines

György Várady, Péter Ábrányi‐Balogh, György M. Keserű, Tı́mea Imre et al.
5 citations
Bioconjugate Chemistry
Monoclonal and Polyclonal Antibodies Research
2.02
article

Site-Selective Antibody Conjugation with Dibromopyrazines

György Várady, Péter Ábrányi‐Balogh, György M. Keserű, Tı́mea Imre, Péter A. Szijj, László Petri, Dénes Szepesi Kovács, József Tóvári, Bettina Pásztor, Enikő Tátrai, József Simon
article en
5 citations

Abstract

In recent years, antibody conjugates have evolved as state-of-the-art options for diagnostic and therapeutic applications. During site-selective antibody conjugation, incomplete rebridging of antibody chains limits the homogeneity of conjugates and calls for the development of new rebridging agents. Herein, we report a dibromopyrazine derivative optimized to reach highly homogeneous conjugates rapidly and with high conversion on rebridging of trastuzumab, even providing a feasible route for antibody modification in acidic conditions. Furthermore, coupling a fluorescent dye and a cytotoxic drug resulted in effective antibody conjugates with excellent serum stability and <i>in vitro</i> selectivity, demonstrating the utility of the dibromopyrazine rebridging agent to produce on-demand future antibody conjugates for diagnostic or therapeutic applications.

Bioconjugate ChemistryVol. 35(9)
Eötvös Loránd University (HU), Budapest University of Technology and Economics (HU), National Institute of Oncology (HU), University College London (GB), HUN-REN Research Centre for Natural Sciences (HU)
Budapesti Műszaki és Gazdaságtudományi Egyetem, University College London, Magyar Tudományos Akadémia, Eötvös Loránd Tudományegyetem, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
Zero hunger
Openalex Percentile: Top 13%
Monoclonal and Polyclonal Antibodies Research
2.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.